Xuehua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuehua Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ni Xiong
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3 shared publications - Zhaohui Wang
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3 shared publications - Yan Wang
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2 shared publications - Yanling Huang
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2 shared publications - Han Li
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
1 shared publication - Han Li
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 16 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 201
The Role of the NF-κB Signaling Pathway in Atherosclerotic Plaque Rupture and Targeted Therapeutic Strategies
Atherosclerosis (AS) is a disease characterized by chronic vascular wall inflammation and lipid deposition. Although lipid-lowering drugs such as statins have significantly reduced cardiovascular event rates, “residual inflammatory risk” remains a key factor driving disease progression and plaque rupture. As a central regulator of the inflammatory response, the nuclear factor-κappaB (NF-κB) signaling network comprises both canonical pro-inflammatory pathways and functionally more complex non-canonical pathways. Increasing evidence in recent years indicates that abnormal and sustained activation of the non-canonical NF-κB signaling pathway plays a pivotal role in driving plaque rupture. This review first elaborates on the shift in AS strategies from “lipid-lowering” to “anti-inflammatory” approaches, followed by an in-depth analysis of the molecular activation mechanisms of the NF-κB signaling pathway and its distinctiveness in the AS pathological process, along with its epigenetic regulation. It emphasizes how this pathway drives pathological angiogenesis and regulates vascular smooth muscle cell (VSMC) phenotypic switching and macrophage function, thereby forming a vicious cycle that amplifies inflammation and structural damage, ultimately leading to acute cardiovascular events. Finally, we systematically summarize current progress and challenges in drug development targeting the NF-κB pathway (e.g., targeting key kinases like NIK and IKKα), aiming to provide theoretical foundations and future directions for novel therapeutic strategies to stabilize coronary plaques and prevent acute coronary syndromes.
- 16 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 201
Top Cited PapersOpen AccessThe Role of the NF-κB Signaling Pathway in Atherosclerotic Plaque Rupture and Targeted Therapeutic Strategies
Atherosclerosis (AS) is a disease characterized by chronic vascular wall inflammation and lipid deposition. Although lipid-lowering drugs such as statins have significantly reduced cardiovascular event rates, “residual inflammatory risk” remains a key factor driving disease progression and plaque rupture. As a central regulator of the inflammatory response, the nuclear factor-κappaB (NF-κB) signaling network comprises both canonical pro-inflammatory pathways and functionally more complex non-canonical pathways. Increasing evidence in recent years indicates that abnormal and sustained activation of the non-canonical NF-κB signaling pathway plays a pivotal role in driving plaque rupture. This review first elaborates on the shift in AS strategies from “lipid-lowering” to “anti-inflammatory” approaches, followed by an in-depth analysis of the molecular activation mechanisms of the NF-κB signaling pathway and its distinctiveness in the AS pathological process, along with its epigenetic regulation. It emphasizes how this pathway drives pathological angiogenesis and regulates vascular smooth muscle cell (VSMC) phenotypic switching and macrophage function, thereby forming a vicious cycle that amplifies inflammation and structural damage, ultimately leading to acute cardiovascular events. Finally, we systematically summarize current progress and challenges in drug development targeting the NF-κB pathway (e.g., targeting key kinases like NIK and IKKα), aiming to provide theoretical foundations and future directions for novel therapeutic strategies to stabilize coronary plaques and prevent acute coronary syndromes.
- Open Access
- 30 December 2025
- Published by MDPI AG in Biomolecules
- Vol. 16 (1) , 58
Optimizing Extracellular Vesicles for Cardiac Repair Post-Myocardial Infarction: Approaches and Challenges
Ischemic heart disease remains the leading cause of cardiovascular mortality worldwide. In myocardial infarction (MI), extracellular vesicles (EVs)—particularly small EVs (sEVs)—transport therapeutic cargo such as miR-21-5p, which suppresses apoptosis, and other proteins, lipids, and RNAs that can modulate cell death, inflammation, angiogenesis, and remodeling. This review synthesizes recent mechanistic and preclinical evidence on native and engineered EVs for post-MI repair, mapping therapeutic entry points across the MI timeline (acute injury, inflammation, and healing) and comparing EV sources (stem-cell and non-stem-cell), administration routes, and dosing strategies. We highlight engineering approaches—including surface ligands for cardiac homing, rational cargo loading to enhance potency, and biomaterial depots to prolong myocardial residence—that aim to improve tropism, durability, and efficacy. Manufacturing and analytical considerations are discussed in the context of contemporary guidance, with emphasis on identity, purity, and potency assays, as well as safety, immunogenicity, and pharmacology relevant to cardiac populations. Across small- and large-animal models, EV-based interventions have been associated with reduced infarct/scar burden, enhanced vascularization, and improved ventricular function, with representative preclinical studies reporting approximately 25–45% relative reductions in infarct size in rodent and porcine MI models, despite substantial heterogeneity in EV sources, formulations, and outcome reporting that limits cross-study comparability. We conclude that achieving clinical translation will require standardized cardiac-targeting strategies, validated good manufacturing practice (GMP)-compatible manufacturing platforms, and harmonized potency assays, alongside rigorous, head-to-head preclinical designs, to advance EV-based cardiorepair toward clinical testing.
- 30 December 2025
- Published by MDPI AG in Biomolecules
- Vol. 16 (1) , 58
Open AccessOptimizing Extracellular Vesicles for Cardiac Repair Post-Myocardial Infarction: Approaches and Challenges
Ischemic heart disease remains the leading cause of cardiovascular mortality worldwide. In myocardial infarction (MI), extracellular vesicles (EVs)—particularly small EVs (sEVs)—transport therapeutic cargo such as miR-21-5p, which suppresses apoptosis, and other proteins, lipids, and RNAs that can modulate cell death, inflammation, angiogenesis, and remodeling. This review synthesizes recent mechanistic and preclinical evidence on native and engineered EVs for post-MI repair, mapping therapeutic entry points across the MI timeline (acute injury, inflammation, and healing) and comparing EV sources (stem-cell and non-stem-cell), administration routes, and dosing strategies. We highlight engineering approaches—including surface ligands for cardiac homing, rational cargo loading to enhance potency, and biomaterial depots to prolong myocardial residence—that aim to improve tropism, durability, and efficacy. Manufacturing and analytical considerations are discussed in the context of contemporary guidance, with emphasis on identity, purity, and potency assays, as well as safety, immunogenicity, and pharmacology relevant to cardiac populations. Across small- and large-animal models, EV-based interventions have been associated with reduced infarct/scar burden, enhanced vascularization, and improved ventricular function, with representative preclinical studies reporting approximately 25–45% relative reductions in infarct size in rodent and porcine MI models, despite substantial heterogeneity in EV sources, formulations, and outcome reporting that limits cross-study comparability. We conclude that achieving clinical translation will require standardized cardiac-targeting strategies, validated good manufacturing practice (GMP)-compatible manufacturing platforms, and harmonized potency assays, alongside rigorous, head-to-head preclinical designs, to advance EV-based cardiorepair toward clinical testing.
- Open Access
- 19 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1268
HCTG-Net: A Hybrid CNN–Transformer Network with Gated Fusion for Automatic ECG Arrhythmia Diagnosis
Accurate detection of cardiac arrhythmias from electrocardiogram (ECG) signals is essential for the early diagnosis of cardiovascular diseases but remains challenging due to the complex, non-linear nature of ECG waveforms. This study proposes HCTG-Net, a Hybrid CNN–Transformer Network with Gated Fusion, designed to jointly capture local morphological features and long-range temporal dependencies in ECG data. The model employs a dual-branch architecture, where a residual CNN extracts localized waveform patterns and a Transformer branch models global temporal context. A learnable gated fusion mechanism adaptively balances and integrates features from both branches at the per-dimension level. Experiments conducted on the MIT-BIH Arrhythmia Database demonstrate that HCTG-Net achieves superior performance compared with existing methods, reaching an overall accuracy of 0.9946 and F1-score of 0.9711. Visualization results show well-clustered feature distributions, confirming robust feature learning, while ablation studies verify the complementary roles of the CNN, Transformer, and fusion modules. Overall, HCTG-Net offers a powerful and adaptive framework for automatic ECG-based arrhythmia diagnosis and holds strong potential for real-time clinical and wearable healthcare applications.
- 19 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1268
Open AccessHCTG-Net: A Hybrid CNN–Transformer Network with Gated Fusion for Automatic ECG Arrhythmia Diagnosis
Accurate detection of cardiac arrhythmias from electrocardiogram (ECG) signals is essential for the early diagnosis of cardiovascular diseases but remains challenging due to the complex, non-linear nature of ECG waveforms. This study proposes HCTG-Net, a Hybrid CNN–Transformer Network with Gated Fusion, designed to jointly capture local morphological features and long-range temporal dependencies in ECG data. The model employs a dual-branch architecture, where a residual CNN extracts localized waveform patterns and a Transformer branch models global temporal context. A learnable gated fusion mechanism adaptively balances and integrates features from both branches at the per-dimension level. Experiments conducted on the MIT-BIH Arrhythmia Database demonstrate that HCTG-Net achieves superior performance compared with existing methods, reaching an overall accuracy of 0.9946 and F1-score of 0.9711. Visualization results show well-clustered feature distributions, confirming robust feature learning, while ablation studies verify the complementary roles of the CNN, Transformer, and fusion modules. Overall, HCTG-Net offers a powerful and adaptive framework for automatic ECG-based arrhythmia diagnosis and holds strong potential for real-time clinical and wearable healthcare applications.